Results 251 to 260 of about 17,703,275 (296)

Pharmacophore screening, molecular docking, and MD simulations for identification of VEGFR-2 and c-Met potential dual inhibitors. [PDF]

Front Pharmacol
Dong J, Hao X.
europepmc   +1 more source

Furan- and Furopyrimidine-Based Derivatives: Synthesis, VEGFR-2 Inhibition, and <i>In Vitro</i> Cytotoxicity. [PDF]

ACS Med Chem Lett
Abd El-Haleem AH, Kassem MAE, Elnagar MR, Abbas SE, El Kerdawy AM, Farouk AKBAW.   +5 more
europepmc   +1 more source

Integrated in silico and in vitro exploration of the anti-VEGFR-2 activities of a semisynthetic xanthine alkaloid inhibiting breast cancer. [PDF]

PLoS One
Elkaeed EB, Elkady H, Khattab AM, Yousef RG, Al-Ghulikah HA, Husein DZ, Ibrahim IM, Elkady MA, Metwaly AM, Eissa IH.   +9 more
europepmc   +1 more source

Dual VEGFR-2 and EGFR^T790M inhibitors of phenyldiazenes: anticancer evaluations, ADMET, docking, design and synthesis. [PDF]

Future Med Chem
Alsulaimany M, Aljohani AKB, Abd El-Sattar NEA, Almadani SA, Alatawi OM, Alharbi HY, Aljohani MS, Al-Shareef AH, Alghamdi R, Tayeb SM, Keshek DE, El-Adl K, Anwer KE.   +12 more
europepmc   +1 more source

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma

Cancers, 2021
Vascular endothelial growth factor (VEGF-A) plays an essential role in tumor-associated angiogenesis, exerting its biological activity by binding and activating membrane receptors, as vascular endothelial growth factor receptor 1 and 2 (VEGFR-1, VEGFR-2).
Catarina Nascimento, Andreia Gameiro, Jorge Correia   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Development And Strategies Of VEGFR-2/KDR Inhibitors

Future Medicinal Chemistry, 2012
VEGF is an important signaling protein involved in both vasculogenesis and angiogenesis. As an essential receptor protein tyrosine kinase propagating cellular signal transduction processes, VEGFR-2 is a central target for drug discovery against tumor-associated angiogenesis.
Lingyi, Huang, Zhengui, Huang, Zhiqiang, Bai, Rui, Xie, Liping, Sun, Kejiang, Lin   +5 more
openaire   +2 more sources

An Integrated Virtual Screening Approach for VEGFR-2 Inhibitors

Journal of Chemical Information and Modeling, 2013
In recent years, various virtual screening (VS) tools have been developed, and many successful screening campaigns have been showcased. However, whether by conventional molecular docking or pharmacophore screening, the selection of virtual hits is based on the ranking of compounds by scoring functions or fit values, which remains the bottleneck of VS ...
Yanmin Zhang, Shangyan Yang, Yu Jiao, Haichun Liu, Haoliang Yuan, Shuai Lu, Ting Ran, Sihui Yao, Zhipeng Ke, Jinxing Xu, Xiao Xiong, Yadong Chen 0001, Tao Lu   +12 more
openaire   +2 more sources

An updated patent review of VEGFR-2 inhibitors (2017-present)

Expert Opinion on Therapeutic Patents, 2021
Introduction: Angiogenesis is a vital process for cellular functions in both physiological and pathophysiological conditions and is one of the hallmarks of cancer progression and metastasis. VEGF/VEGFR-2 signaling pathway has been recognized as the most critical factor in promoting angiogenesis.
Thoraya A, Farghaly, Wedian A, Al-Hasani, Hanan Gaber, Abdulwahab   +2 more
openaire   +2 more sources

VEGFR‐2 is downregulated in sestamibi‐negative parathyroid adenomas

Head & Neck, 2019
AbstractBackgroundThe purpose of this study was to determine the expression profile of several biomarkers in sestamibi‐positive (n = 23) and sestamibi‐negative (n = 6) parathyroid adenomas.MethodsA tissue microarray of parathyroid adenomas from 29 patients was constructed and slides were stained for several proteins involved in angiogenesis ...
Boban M. Erovic, David P. Goldstein, Sylvia L. Asa, Stefan Janik, Ozgur Mete, Jonathan C. Irish   +5 more
openaire   +2 more sources

Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2

Bioorganic & Medicinal Chemistry, 2021
A series of phenylurea hydroxamic acids incorporating pharmacophores of inhibitors of HDAC inhibitors and VEGFR-2 has been designed. Most of the compounds show antiproliferative activity comparable to that of Vorinostat and Sorafenib, and better EPC inhibitory activity.
Szu, Lee, Shih-Wei, Wang, Chen-Lin, Yu, Huai-Ching, Tai, Juei-Yu, Yen, Yu-Lien, Tuan, Hsueh-Hsiao, Wang, Yi-Ting, Liu, Shiou-Sheng, Chen, Hsueh-Yun, Lee   +9 more
openaire   +2 more sources